A Phase II Study of Single Agent Depsipeptide (FK228; NSC 630176; IND 51,810) in Patients With Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase of Trial: Phase II
Latest Information Update: 22 May 2015
At a glance
- Drugs Romidepsin (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 16 Nov 2008 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov.
- 12 Aug 2005 New trial record.